NASDAQ: NBIX

Neurocrine Biosciences (NBIX) Stock Analysis & Forecast

Nov 13 close

$167.40−2.00 (−1.2%)

Gekko Brief

Nov 9 close

Neurocrine Biosciences closed at $168.86 on 9 November 2026, +2.6% on the day. The price sits between the 50-day ($147.51) and 200-day ($148.18) moving averages, inside a 52-week range of $122.14 to $186.12. The GekkoIndex reads 40.5, in the Distribution zone, down 15 points over five sessions. Gekko Fair Value is $249.09, so the price is 32.2% below it.

The next earnings report is due on 10 February 2027, 87 days away. Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 10% across the report. Seasonally, the next 20 trading days from this point averaged -1.6% over the last 5 years, rising in 3 of them.

20 firms rate the stock: 17 buy, 3 hold and 0 sell, with a consensus target of $207.50. A typical daily move is about 3.4%, and a typical 20-day move about 6.1%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (gekkoindex).

A plain summary of the figures as of the Nov 9, 2026 close.

Neurocrine Biosciences price vs fair value

▲$235.42$167.40Nov ’25May ’26Nov ’26
Close $167.40200-day averageGekko Fair Value $235.42

Neurocrine Biosciences quick facts

Market cap
$16.94B
P/E ratio
25.1
Forward P/E
17.1
EPS, TTM
$6.74
Revenue, TTM
$3.70B
Profit margin
19%
Dividend yield
—
Beta
0.33
Volume
1.37M avg 1.44M
1-year return
+14.0%
Typical daily move
±3.8%
Typical 20-day move
±6.1%
50-day average
$148.58
200-day average
$148.88
Next earnings
Feb 10
Shares outstanding
101.2M
52-week range
$122.14$186.12

Neurocrine Biosciences swing-trade checklist

Neurocrine Biosciences scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $167.40 sits between the 50-day ($148.58) and 200-day ($148.88) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    46.6, Neutral

    Reading 46.6 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    28.9% below

    Price is 28.9% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 87 days

    Next report Feb 10, 2027, 87 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.5% on average

    From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Neurocrine Biosciences stock chart and price history

Neurocrine Biosciences closed at $167.40 on Nov 13, 2026, +14.0% over the past year, inside a 52-week range of $122.14 to $186.12.

Close50-day average200-day averageVolume
Neurocrine Biosciences share price, past year, with 50-day and 200-day moving averages and volume$120$140$160$180DecJan 2026FebMarAprMayJunJulAugSepOctNov167.40

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+22.2%
3 months
+8.4%
6 months
+5.7%
1 year
+14.0%
The full NBIX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NBIX in Gekko

Follow Neurocrine Biosciences through every session

Put NBIX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track NBIX in GekkoFree for 7 days. No credit card required.

About Neurocrine Biosciences

Neurocrine Biosciences develops and sells medicines aimed at neurological, endocrine, and psychiatric disorders. Its best-known product is INGREZZA, a treatment for tardive dyskinesia, and the company also markets ONGENTYS for use alongside levodopa therapy in Parkinson's disease, ORILISSA for pain tied to endometriosis, and ORIAHNN, a non-surgical oral option for heavy menstrual bleeding caused by uterine fibroids.

Beyond its marketed treatments, the company runs a pipeline of experimental compounds addressing conditions such as focal epilepsy, rare pediatric epilepsy, essential tremor, major depressive disorder, anhedonia linked to depression, and schizophrenia. It pursues some of this work through licensing and collaboration agreements with other pharmaceutical and biotech organizations, including Heptares Therapeutics, Takeda, Idorsia, Xenon Pharmaceuticals, Voyager Therapeutics, BIAL Portela, Mitsubishi Tanabe Pharma, and AbbVie.

Neurocrine Biosciences was established in 1992 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker NBIX.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
neurocrine.com

Neurocrine Biosciences GekkoIndex: the smart money zone

Neurocrine Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.6, in the Neutral zone, up 5.6 points over five sessions.

010046.6Neutral

Up 5.6 points over five sessions, from the Distribution zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying33+0.9%+2.0%+1.5%+5.9%
Accumulation240+0.2%+0.4%+1.2%+7.2%
Neutral (current zone)394+0.2%+0.4%+0.3%−1.5%
Distribution24−0.9%−2.1%+0.4%−0.6%
Selling11+1.7%−0.8%−4.0%−0.6%

Average NBIX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the NBIX price, zone by zone.Track NBIX in Gekko

Is Neurocrine Biosciences stock overvalued? Gekko Fair Value

Neurocrine Biosciences trades 28.9% below Gekko Fair Value of $235.42, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Neurocrine Biosciences shares are worth, recalculated every trading day.

$235.42

Gekko Fair Value, Nov 14, 2026

28.9% Undervalued

At the end of Aug 2026 the price was 41.5% below the estimate.

Gekko Fair ValueShare price, month end
$235$167Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open NBIX in Gekko

Neurocrine Biosciences insider and Congress trading

No open-market insider purchases were filed for Neurocrine Biosciences, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for NBIX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every NBIX insider filing, plotted on the chart in Gekko.Open NBIX in Gekko

Congress trades last 90 days

No trades in NBIX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for NBIX, plotted on the chart in Gekko.Open NBIX in Gekko

Buybacks

Neurocrine Biosciences has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$92.10M
As a share of market cap
0.54%

From company filings.

Hedge funds and billionaires quarter ended Jun 30

0of the funds Gekko tracks hold NBIX.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Neurocrine Biosciences earnings: next date and track record

Neurocrine Biosciences reports on Feb 10, 2027 (87 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±10%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−18.9%Feb ’25+8.4%May ’25−4.4%Jul ’25−7.3%Oct ’25−10.6%Feb ’26+9.7%May ’26−7.7%Jul ’26+12.8%Nov ’26

Last earnings call, Nov 2, 2026 AI summary

What they said
Neurocrine Biosciences reported record Q3 2026 net product sales exceeding $1.1 billion, up 40%+ year-over-year, with record non-GAAP EPS above $3 per share. INGREZZA generated $801M (up 17% YoY), CRENESSITY contributed $211M, and VYKAT XR added $107M. The company raised full-year INGREZZA guidance to $2.9-$2.925 billion, citing high-teens prescription growth. Phase III data readouts for osavampator and direclidine are anticipated in 2027.
Guidance
Full-year INGREZZA guidance raised to $2.9-$2.925 billion; Q3 results include $20M timing benefit expected to reverse in Q4. Management expects continued double-digit INGREZZA volume growth in 2027, partially offset by mid- to high single-digit net pricing headwinds. Formal 2027 guidance to be provided in February.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 2, 2026$3.29
est $1.91
+72.3%$1.12B
est $1.04B
+7.6%+12.8%
Jul 30, 2026$2.36
est $1.88
+25.5%$959.0M
est $891.2M
+7.6%−7.7%
May 5, 2026$1.94
est $1.70
+14.1%$814.5M
est $768.3M
+6.0%+9.7%
Feb 11, 2026$1.88
est $1.80
+4.4%$805.5M
est $790.5M
+1.9%−10.6%
Oct 28, 2025$2.17
est $2.07
+4.8%$794.9M
est $806.8M
−1.5%−7.3%
Jul 30, 2025$1.06
est $0.98
+8.2%$687.5M
est $746.4M
−7.9%−4.4%
May 5, 2025$0.08
est $0.54
−85.0%$572.6M
est $559.6M
+2.3%+8.4%
Feb 6, 2025$1.69
est $1.93
−12.4%$627.7M
est $629.4M
−0.3%−18.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Neurocrine Biosciences stock forecast and analyst price targets

Analysts’ average 12-month price target for Neurocrine Biosciences is $208.11, +24.3% from the last close, from 20 firms rating the stock in the last 90 days.

$208.11consensus 12-month target, +24.3% from the last close
Low $150High $253
Buy17
Hold3
Sell0

Each firm’s latest rating in the last 90 days: 20 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13Morgan StanleyHold, maintained$191+14.1%
Nov 3Canaccord GenuityBuy, reiterated$220+31.4%
Nov 3Morgan StanleyHold, reiterated$185+10.5%
Nov 3Piper SandlerBuy, reiterated$215+28.4%
Nov 3Wells FargoBuy, reiterated$200+19.5%
+0.3%average 20-day move after past Neutral readings
+2.5%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Neurocrine Biosciences seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Neurocrine Biosciences averaged +2.5% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−5.8%2021+0.8%2022+9.9%2023+3.1%2024+6.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.6%1 of 5
Next 10 trading days+0.8%4 of 5
Next 15 trading days+1.9%4 of 5
Next 20 trading days+2.5%4 of 5
Next 30 trading days+4.5%3 of 5

For scale, NBIX’s typical 20-trading-day move in either direction is about 6.1%.

Neurocrine Biosciences market cap and key statistics

Neurocrine Biosciences’s market cap is $16.94B, with a P/E ratio of 25.1 and revenue of $3.70B over the last twelve months.

Valuation

Market cap
$16.94B
P/E ratio
25.1
Forward P/E
17.1
EPS, TTM
$6.74
Gekko Fair Value
$235.42

Trading

Volume
1.37M
Avg volume, 20 days
1.44M
52-week high
$186.12
52-week low
$122.14
Shares outstanding
101.2M

Financials

Revenue, TTM
$3.70B
Profit margin
19%
Return on equity
20.4%
Quarterly earnings growth, YoY
−3.9%

Risk and income

Beta
0.33
Typical daily move
±3.8%
Typical 20-day move
±6.1%

Neurocrine Biosciences peers

Neurocrine Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Neurocrine Biosciences stock FAQ

What is Neurocrine Biosciences’s market cap?

Neurocrine Biosciences’s market cap is $16.94B at the Nov 13, 2026 close of $167.40, with 101.2M shares outstanding. The shares trade on a P/E ratio of 25.1.

What is the Neurocrine Biosciences stock forecast?

The consensus analyst 12-month price target for Neurocrine Biosciences is $208.11, +24.3% from the last close. Of the 20 firms that rated the stock in the last 90 days, 17 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Neurocrine Biosciences stock overvalued or undervalued?

On Gekko’s estimate Neurocrine Biosciences is undervalued: the Nov 13, 2026 close of $167.40 is 28.9% below Gekko Fair Value of $235.42. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Neurocrine Biosciences report earnings next?

Neurocrine Biosciences is expected to report on Feb 10, 2027 (87 days away). Analysts expect earnings of $2.07 per share on revenue of $1.09B. Neurocrine Biosciences beat the earnings estimate in 6 of its last 8 reports, moving 10% on average across the report.

What is Neurocrine Biosciences’s 52-week high and low?

Neurocrine Biosciences’s 52-week high is $186.12 and its 52-week low is $122.14; it closed at $167.40 on Nov 13, 2026, +14.0% over the past year.

Is Neurocrine Biosciences stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (fair value, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Neurocrine Biosciences the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.